Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Real-time Estimate Cboe BZX Other stock markets 15:11:05 2024-06-26 EDT			5-day change	1st Jan Change
18.2 ^USD	+0.91%		-4.93%	+22.10%

06-04	Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	MT
06-03	Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial	06-03	CI
Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany	05-23	CI
NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	05-02	MT
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	05-02	MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure	05-02	AN
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M	05-02	MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	04-24	CI
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	04-05	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	03-27	MT
Novocure Q4 Net Loss Widens, Revenue Rises	02-22	MT
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $133.8M	02-22	MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise	01-18	MT
Novocure Shares Rise 17% After FDA Accepts Pre-Market Application	01-18	DJ
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer	01-18	CI
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma	01-09	CI
NovoCure Reports Higher Q4 Preliminary Revenue; Shares Rise	01-08	MT
Novocure Preliminary Full Year 2023 Net Revenues Of $509 Mln And Q4 Net Revenues Of $134 Mln	01-08	RE
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability	11-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Highlights

Filters